Comercialización del antidepresivo NOVOHUMORAP post pandemia COVID 19 en la ciudad de Guayaquil.

Abstract

After the events caused by the global Covid 19 pandemic, not only were respiratory health problems left behind, but cases of mental health care such as depression, stress and anxiety increased, causing an increase in the demand for medicines to treat these ailments, it is for this reason that the general objective of this essay is defined in analyzing the commercialization of the antidepressant NOVO HUMORAP post pandemic Covid 19 in the city of Guayaquil. Zone 1 of the city of Guayaquil was determined as the study segment, of which the findings found in the investigation focus on a commercial level, evidencing an increase of 19%, as well as knowing that the direct competition is E Zentius, which has the higher price of NOVO HUMORAP of 15%, the results in zone 1 of Guayaquil were found to have greater demand, evidencing that with respect to the competition the gap decreased in the year 2023 at the end of June with 0.72%, with expectations of that the year closes above the competition with the strategies implemented in the commercial area. It is suggested at the end of the essay that it would be important to continue research on the increase in mental health cases, especially in young people, as well as on the sales trend at the national level of sales in dollars and quantity of drugs.